Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors: Primary liver tumors

Surgical Oncology Clinics of North America

Volumn 5, Issue 2, 1996, Pages 429-441

  Lowy, A M ^a   Curley, S A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; FILTRATION; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LIVER TUMOR; LIVER VEIN; MALE; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

EID: 0029998792     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30392-2     Document Type: Article

References (18)

1. Bern M.M. McDermott W. Cady B. Intra-arterial hepatic infusion and intravenous Adriamycin for treatment of hepatocellular carcinoma Cancer 42 1978 399 405
2. Curley S.A. Byrd D.R. Newman R.A. Hepatic arterial infusion chemotherapy with complete hepatic venous isolation and extracorporeal chemofiltration: A feasibility study of a novel system Anticancer Drugs 2 1991 175 183
3. Curley S.A. Byrd D.R. Newman R.A. Reduction of systemic drug exposure following hepatic arterial infusion of doxorubicin with complete hepatic venous isolation and ex-tracorporeal chemofiltration Surgery 114 1993 579 585
4. Curley S.A. Newman R.A. Dougherty R.A. A novel system to treat human hepatocellular carcinoma: A phase I study Ann Surg Oncol 1 1994 389 399
5. Curley S.A. Stone D.L. Fuhrman G.M. Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration Cancer Chemother Pharmacol 33 1993 251 257
6. Frei E. Canellos G.P. Dose: A critical factor in cancer chemotherapy Am J Med 69 1980 585 594
7. Hohn D.C. Melnick J. Stagg R.J. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine J Clin Oncol 3 1985 98 102
8. Hohn D.C. Stagg R.J. Friedman M.A. A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial J Clin Oncol 7 1989 1646 1654
9. Kemeny M.M. Battiforah Blayney D.W. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR Ann Surg 202 1985 176 181
10. Kemeny N. Daly J. Olderman P. Hepatic artery pump infusion: Toxicity and results in patients with metastatic colorectal carcinoma J Clin Oncol 2 1984 595 600
11. Kemeny N. Daly J. Reichman B. Intrahepatic or systemic infusion of fluorodeoxy-uridine in patients with liver metastases from colorectal carcinoma Ann Intern Med 107 1987 459 465
12. Khayat D. Le Cesne A. Weil M. Intra-arterial treatment of hepatic metastases using 5-fluorouracil, Adriamycin, mitomycin C (FAM) chemotherapeutic regimen Regional Cancer Treatment 1 1988 62 64
13. Legha S.S. Benjamin R.S. Mackay B. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion Ann Intern Med 96 1982 133 139
14. Nakamura S. Tsuzuki T. Surgical anatomy of the hepatic veins and the inferior vena cava Surg Gynecol Obstet 152 1981 43 50
15. O’Connell M.J. Hahn R.G. Rubin J. Chemotherapy of malignant hepatomas with sequential intra-arterial doxorubicin and systemic 5-fluorouracil and semustine Cancer 62 1988 1041 1043
16. Sasaki Y. Imaoka S. Hasegawa Y. Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer Cancer 55 1985 311 316
17. Schwartz S.I. Primary malignant tumors Wanebo J.H. Hepatic and Biliary Cancer 1987 Marcel Dekker New York 3 15
18. Wright K.C. Wallace S. Benjamin R.S. Experimental comparison between hepatic artery infusion and occlusion of Adriamycin Cancer Drug Delivery 4 1987 33 41